TITLE

Hepatotoxicity of Rifampin-Pyrazinamide and Isoniazid Preventive Therapy and Tuberculosis Treatment

AUTHOR(S)
van Hest, Rob; Baars, Hennie; Kik, Sandra; van Gerven, Paul; Trompenaars, Marie-Christine; Kalisvaart, Nico; Keizer, Sytze; Borgdorff, Martien; Mensen, Marlies; Cobelens, Frank
PUB. DATE
August 2004
SOURCE
Clinical Infectious Diseases;8/15/2004, Vol. 39 Issue 4, p488
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. Severe liver injury has been attributed to preventive treatment of latent tuberculosis infection with a 2-month course of rifampin-pyrazinamide. Methods. A retrospective cohort study in The Netherlands compared the hepatotoxicity of preventive treatment with rifampin-pyrazinamide with that of preventive treatment with isoniazid, and also with that of treatment for active tuberculosis containing at least isoniazid, rifampin, and pyrazinamide. Results. Preventive treatment with rifampin-pyrazinamide caused severe hepatotoxicity more often than did preventive treatment with isoniazid (odds ratio [OR], 2.61; 95% confidence interval [CI], 1.26-5.39; P = .012), especially in patients <25 years old. it also caused severe hepatotoxicity more often than triple- or quadruple-drug tuberculosis treatment (OR, 2.61; 95% CI, 1.2 1-5.59; P = .016), especially if the pyrazinamide dose was ≥30 mg/kg. Preventive treatment with rifampin-pyrazinamide was more hepatotoxic even when the advised pyrazinamide dose of up to 20 mg/kg for preventive treatment was compared with the pyrazinamide dose of 30 mg/kg for tuberculosis treatment. Conclusions. Preventive treatment with rifampin-pyrazinamide causes severe hepatotoxicity more often than does preventive treatment with isoniazid or curative treatment for tuberculosis.
ACCESSION #
14048040

 

Related Articles

  • Rifampin and Pyrazinamide for Latent Tuberculosis Infection: Clinical Trials and General Practice. Saukkonen, Jussi // Clinical Infectious Diseases;8/15/2004, Vol. 39 Issue 4, p566 

    The article focuses on the use of rifampin and pyrazinamide for the treatment of latent tuberculosis infection (LTBI). As the prevalence of active tuberculosis decreases in the U.S., the focus on treatment of LTBI has intensified. One of these LTBI regimens, a 2-month course of rifampin with...

  • Safety of 3 Different Reintroduction Regimens of Antituberculosis Drugs after Development of Antituberculosis Treatment-Induced Hepatotoxicity. Sharma, Surendra K.; Singla, Rohit; Sarda, Pawan; Mohan, Alladi; Makharia, Govind; Jayaswal, Arvind; Sreenivas, Vishnubhatla; Singh, Sarman // Clinical Infectious Diseases;3/15/2010, Vol. 50 Issue 6, p833 

    Background. Drug-induced hepatotoxicity (DIH) is the most common adverse drug reaction leading to interruption of antituberculosis treatment. Worldwide, different reintroduction regimens have been advocated, but no consensus guidelines are available. Reintroduction of antituberculosis drugs in...

  • Protective Effects of Metallothionein on Isoniazid and Rifampicin-Induced Hepatotoxicity in Mice. Lian, Yong; Zhao, Jing; Xu, Peiyu; Wang, Yimei; Zhao, Jun; Jia, Li; Fu, Ze; Jing, Li; Liu, Gang; Peng, Shuangqing // PLoS ONE;Aug2013, Vol. 8 Issue 8, p1 

    Isoniazid (INH) and Rifampicin (RFP) are widely used in the world for the treatment of tuberculosis, but the hepatotoxicity is a major concern during clinical therapy. Previous studies showed that these drugs induced oxidative stress in liver, and several antioxidants abated this effect....

  • Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. Anne Aspler // Thorax;Jul2010, Vol. 65 Issue 7, p582 

    RATIONALE: Treatment for latent tuberculosis infection with isoniazid for 9 months (9INH) has poor completion and serious adverse events, while treatment for 4 months with daily rifampin (4RIF) has significantly higher completion and fewer adverse events. OBJECTIVES: To compare the health...

  • Isoniazid.  // Reactions Weekly;Feb2015, Vol. 1540 Issue 1, p173 

    The article presents a case study of a 59-year-old woman who developed fatal hepatotoxicity after receiving isoniazid treatment for tuberculosis.

  • A Retrospective Evaluation of Completion Rates, Total Cost, and Adverse Effects for Treatment of Latent Tuberculosis Infection in a Public Health Clinic in Central Massachusetts. Young, Heather; Wessolossky, Mireya; Ellis, Jeanne; Kaminski, Martin; Daly, Jennifer S. // Clinical Infectious Diseases;8/1/2009, Vol. 49 Issue 3, p424 

    Completion rates, total cost, and adverse effects were compared for patients in central Massachusetts treated for latent tuberculosis infection with 9 months of isoniazid or 4 months of rifampin. Although the adverse effects were similar between the 2 groups, 4 months of rifampin was associated...

  • New Anti-Tuberculosis Drugs with Novel Mechanisms of Action. Riversa, Emma C.; Mancera, Ricardo L. // Current Medicinal Chemistry;2008, Vol. 15 Issue 19, p1956 

    It is estimated that a third of the world's population is currently infected with tuberculosis, leading to 1.6 million deaths annually. The current drug regimen is 40 years old and takes 6-9 months to administer. In addition, the emergence of drug resistant strains and HIV co-infection mean that...

  • Better tolerability makes rifampicin cheaper option for latent TB.  // PharmacoEconomics & Outcomes News;8/21/2010, Issue 610, p9 

    The article focuses on the study comparing the costs of rifampicin therapy and the currently recommended standard regiment of nine months of isoniazid for treating latent tuberculosis (TB) by Anne Aspler and colleagues, published in an issue of "Thorax."

  • Turning the tables on TB. PAYNE, RICHARD // Chemistry in Australia;Oct2013, p16 

    The article offers information on the treatment of tuberculosis (TB) using drug comprising a combination therapy of four drugs (rifampicin, isoniazid, ethambutol and pyrazinamide) for six months, alongside observation of the treatment course by a medical professional. However, poor adherence to...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics